Laboratory Safety of Dupilumab in Patients Aged 6–11 Years with Severe Atopic Dermatitis: Results from a Phase III Clinical Trial

BACKGROUND: Previous studies of dupilumab in adolescents and adults with moderate-to-severe atopic dermatitis (AD) showed no clinically meaningful adverse changes in laboratory parameters. OBJECTIVE: The aim of this study was to assess laboratory outcomes in children aged 6–11 years with severe AD i...

Descripción completa

Detalles Bibliográficos
Autores principales: Paller, Amy S., Wollenberg, Andreas, Siegfried, Elaine, Thaçi, Diamant, Cork, Michael J., Arkwright, Peter D., Gooderham, Melinda, Sun, Xian, O’Malley, John T., Khokhar, Faisal A., Vakil, Jignesh, Bansal, Ashish, Rosner, Karli, Shumel, Brad, Levit, Noah A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8418591/
https://www.ncbi.nlm.nih.gov/pubmed/34462864
http://dx.doi.org/10.1007/s40272-021-00459-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8418591/
https://www.ncbi.nlm.nih.gov/pubmed/34462864
http://dx.doi.org/10.1007/s40272-021-00459-x

Ejemplares similares